Project Grant R21AI193399
Award Date 8/21/25
Completion Date 7/31/27
Dollars Obligated $458K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- This $380,000 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), on August 1, 2025. The purpose of the grant is to develop a bifunctional RNA therapeutic called PS03 to modulate PD-L1 expression on B cells in order to induce exhaustion of diabetogenic T cells and prevent the onset of type 1 diabetes. Preliminary data suggests that systemic administration of PS03 can...
- This $120,255 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the impact of antigen-specific immunotherapy on the differentiation and function of effector T cells in autoimmune diabetic islet transplants. The study aims to determine how inducing tolerance to a hybrid insulin peptide can expand antigen-specific regulatory T cells that suppress autoreactive CD4 and CD8 T...
- The Project Grant award of $429,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research to investigate the role of pH in the pathogenesis of Type 1 Diabetes (T1D). The research, conducted by the University of Colorado-Denver, focuses on understanding how changes in acidity levels within insulin-producing cells can lead to the formation of hybrid insulin peptides (HIPs), which may be...
- This Project Grant award of $634,984 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of a specific B cell subset, termed BND2, in the autoimmune disorder type 1 diabetes (T1D). The research aims to: 1) elucidate the mechanism by which these insulin-reactive BND2 cells become activated and break anergy, 2) determine their fate and function as antigen-presenting...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $287,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). This 2-year project, running from April 2025 to March 2027, aims to determine if genetic mutations that alter IL-17 signaling contribute to the development of autoimmune diabetes. The grant supports UCSF's research to investigate how perturbations to...
- This federal Project Grant award of $801,662, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by the Scripps Research Institute to investigate the early phase of type 1 diabetes. The key objectives are to characterize the antigen-presenting cells associated with pancreatic islets during the pre-diabetic stage in mice, using advanced techniques...
- This Project Grant award of $303,274 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Antiger Therapeutics Inc., a startup biotech company, in developing targeted immunotherapies for Type 1 Diabetes (T1D). The primary objective is to engineer Peptide-HLA-DQ8 complex biologics that can selectively block the pathogenic T cells responsible for the autoimmune response in T1D. This innovative...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...
- The University of Utah was awarded a $423,500 Project Grant on July 22, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will support research to develop clinically viable agents for the targeted depletion of lymphocytes expressing programmed death-1 (PD-1), which could offer a novel solution to halt autoimmune attacks while avoiding long-term lymphopenia or broad immunosuppression. The...
- This Project Grant award of $200,664 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research at the University of California, San Francisco (UCSF) to investigate the immunological mechanisms and biomarkers underlying the development of autoimmune diabetes induced by immune checkpoint inhibitor cancer treatments. The key objectives are to: Analyze genetic predisposition to...